Table of Content

Introduction
Executive Summary
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC): Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
EGF 816 (Nazartinib): Novartis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Mid Stage Products (Phase II)
• Comparative Analysis
APL 101 (Bozitinib): Apollomics Inc.
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Inactive Products
• Comparative Analysis
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Companies
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Products
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Unmet Needs
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Market Drivers and Barriers
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Future Perspectives and Conclusion
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Analyst Views
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Companies
Appendix



List of Figures


Figure 1 Total Products for C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


List of Tables


Table 1 Total Products for C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products